However, individual results vary depending on medication adherence, diet, physical activity, and individual metabolism
Currently available GLP-1 medications in the United States include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide extended-release (Bydureon BCise), and tirzepatide (Mounjaro, Zepbound)with tirzepatide being a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 agonist
Tirzepatide functions by emulating certain hormones that signal satiety
While Mounjaro is primarily indicated for Type 2 diabetes, some studies suggest that Tirzepatide at various doses, including 2.5mg, may be associated with weight changes in certain patients
Our process for determining if you are a candidate for Tirzepatide involves several steps: Tirzepatide offers a promising option for individuals with type 2 diabetes and obesity, providing effective blood sugar control, weight loss, and potential cardiovascular benefits